|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
100 Clinical Results associated with CD16a x BCMA x NCR3
100 Translational Medicine associated with CD16a x BCMA x NCR3
0 Patents (Medical) associated with CD16a x BCMA x NCR3